Research article

Abnormal costimulatory phenotype and function of dendritic cells before and after the onset of severe murine lupus

Lucrezia Colonna¹ , Joudy-Ann Dinnall¹ , Debra K Shivers¹ , Lorenza Frisoni² , Roberto Caricchio² and Stefania Gallucci¹

¹  Laboratory of Dendritic Cell Biology, Division of Rheumatology, Joseph Stokes' Jr. Research Institute, Children's Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, PA 19104-4318, USA

²  Division of Rheumatology, School of Medicine, University of Pennsylvania, 751 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA

author email corresponding author email

Arthritis Research & Therapy 2006, 8:R49doi:10.1186/ar1911

Published:	28 February 2006

Abstract

We analyzed the activation and function of dendritic cells (DCs) in the spleens of diseased, lupus-prone NZM2410 and NZB-W/F1 mice and age-matched BALB/c and C57BL/6 control mice. Lupus DCs showed an altered ex vivo costimulatory profile, with a significant increase in the expression of CD40, decreased expression of CD80 and CD54, and normal expression of CD86. DCs from young lupus-prone NZM2410 mice, before the development of the disease, expressed normal levels of CD80 and CD86 but already overexpressed CD40. The increase in CD40-positive cells was specific for DCs and involved the subset of myeloid and CD8α⁺ DCs before disease onset, with a small involvement of plasmacytoid DCs in diseased mice. In vitro data from bone marrow-derived DCs and splenic myeloid DCs suggest that the overexpression of CD40 is not due to a primary alteration of CD40 regulation in DCs but rather to an extrinsic stimulus. Our analyses suggest that the defect of CD80 in NZM2410 and NZB-W/F1 mice, which closely resembles the costimulatory defect found in DCs from humans with systemic lupus erythematosus, is linked to the autoimmune disease. The increase in CD40 may instead participate in disease pathogenesis, being present months before any sign of autoimmunity, and its downregulation should be explored as an alternative to treatment with anti-CD40 ligand in lupus.